Distinct tau PET dynamics in early versus late age-of-onset Alzheimer’s disease
Konstantinos Chiotis, Ganna Blazhenets, David N. Soleimani-Meigooni, Paul S. Aisen, Alinda Amuiri, Alireza Atri, Laurel Beckett, Michael Brickhouse, David G. Clark, Jeffrey L. Dage, Gregory S. Day, Ranjan Duara, Ani Eloyan, Tatiana Foroud, Neill R. Graff-Radford, Ian M. Grant, Dustin B. Hammers, Lawrence S. Honig, Erik C. B. Johnson, David T. Jones, Kala Kirby, Robert Koeppe, Joel H. Kramer, Walter A. Kukull, Julien Lagarde, Antoine Leuzy, Piyush Maiti, Joseph C. Masdeu, Mario F. Mendez, Erik Musiek, Kelly N. Nudelman, Chiadi U. Onyike, Meghan Riddle, Salma Rocha, Emily Rogalski, Stephen Salloway, Daniel R. Schonhaut, Sharon J. Sha, Ranjani Shankar, Alexander Taurone, Maryanne Thangarajah, Arthur W. Toga, Alexandra Touroutoglou, Raymond Scott Turner, Prashanthi Vemuri, Thomas S. Wingo, David A. Wolk, Kyle Womack, Jiaxiuxiu Zhang, Maria C. Carrillo, Bradford C. Dickerson, Liana G. Apostolova, Renaud La Joie, Gil D. Rabinovici
Early-onset Alzheimer’s disease (EOAD) and late-onset AD (LOAD) differ in clinical presentations and rates of progression. We aimed to compare baseline and longitudinal tau positron emission tomography (PET) burden measured with
18
F-flortaucipir and its relationship with clinical variables in amyloid PET–positive, cognitively impaired participants from the Longitudinal Early-Onset Alzheimer’s Disease Study (EOAD;